STEM-Talk

Episode 192: Ken and Dawn weigh in on ChatGPT, ketamine, urolithin-A, rapamycin, and more in wide-ranging AMA

8 snips
Mar 5, 2026
Wide-ranging science questions get clear, concise treatment. They tackle ChatGPT limitations, LLM training cutoffs, and retrieval strategies. Spacewalk training and why neutral buoyancy helps are explained. Discussions cover urolithin‑A trials, rapamycin’s short-term heart effects, ketamine–mTOR research, lithium links to Alzheimer’s, and L‑citrulline for aging blood vessels.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
ADVICE

Use The Clinical Formulation When Taking Urolithin A

  • If choosing a researched urolithin A supplement, pick the formulation used in clinical trials.
  • Ken recommends Mitopure (Timeline) as the form most consistently used in human studies at 500–1,000 mg/day doses.
INSIGHT

Rapamycin Shows Promising Early Cardiac Signals

  • Low-dose rapamycin has reproducible benefits in animal hearts and promising early human signals for diastolic function.
  • A 2025 pilot (6 men, 1 mg/day for 8 weeks) improved diastolic parameters and nitric-oxide vasodilation but is hypothesis-generating.
INSIGHT

Rapamycin Didn't Block Ketamine's Acute Antidepressant Effect

  • A 2020 Yale pilot challenged the idea that mTOR activation is required for ketamine's acute antidepressant effect.
  • The study (n=20) found rapamycin didn't block ketamine at 24 hours and suggested—but didn't confirm—prolonged durability.
Get the Snipd Podcast app to discover more snips from this episode
Get the app